Obesity, hypertension and aldosterone: is leptin the link?
- PMID: 27252389
- PMCID: PMC8350967
- DOI: 10.1530/JOE-16-0160
Obesity, hypertension and aldosterone: is leptin the link?
Abstract
Obesity is a serious health hazard with rapidly increasing prevalence in the United States. In 2014, the World Health Organization estimated that nearly 2 billion people worldwide were overweight with an estimated 600 million of these obese. Obesity is associated with many chronic diseases, including cardiovascular disease and hypertension. Data from the Framingham Heart study suggest that approximately 78% of the risk for hypertension in men and 65% in women is related to excess body weight, a relationship that is further supported by studies showing increases in blood pressure with weight gain and decreases with weight loss. However, the exact mechanism by which excess body fat induces hypertension remains poorly understood. Several clinical studies have demonstrated elevated plasma aldosterone levels in obese individuals, especially those with visceral adiposity, with decreased aldosterone levels measured in concert with reduced blood pressure following weight loss. Since aldosterone is a mineralocorticoid hormone that regulates blood volume and pressure, serum aldosterone levels may link obesity and hypertension. Nevertheless, the mechanism by which obesity induces aldosterone production is unclear. A recent study by Belin de Chantemele and coworkers suggests that one adipose-released factor, leptin, is a direct agonist for aldosterone secretion; other adipose-related factors may also contribute to elevated aldosterone levels in obesity, such as very low-density lipoprotein (VLDL), the levels of which are elevated in obesity and which also directly stimulates aldosterone biosynthesis. This focused review explores the possible roles of leptin and VLDL in modulating aldosterone secretion to underlie obesity-associated hypertension.
Keywords: adipose tissue; aldosterone; hypertension; leptin; obesity.
© 2016 Society for Endocrinology.
Conflict of interest statement
Declaration of interest
The authors declare no conflict of interest.
Figures

Similar articles
-
Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice.Hypertension. 2016 May;67(5):1020-8. doi: 10.1161/HYPERTENSIONAHA.115.06642. Epub 2016 Mar 7. Hypertension. 2016. PMID: 26953321 Free PMC article.
-
Changes in serum aldosterone are associated with changes in obesity-related factors in normotensive overweight and obese young adults.Hypertens Res. 2013 Oct;36(10):895-901. doi: 10.1038/hr.2013.45. Epub 2013 May 9. Hypertens Res. 2013. PMID: 23657296 Free PMC article. Clinical Trial.
-
Overweight, hypertension and cardiovascular disease: focus on adipocytokines, insulin, weight changes and natriuretic peptides.Dan Med J. 2015 Nov;62(11):B5163. Dan Med J. 2015. PMID: 26522487
-
Obesity hypertension: the emerging role of leptin in renal and cardiovascular dyshomeostasis.Curr Opin Nephrol Hypertens. 2010 Jan;19(1):72-8. doi: 10.1097/MNH.0b013e328332fb49. Curr Opin Nephrol Hypertens. 2010. PMID: 19851106 Review.
-
Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.Circulation. 2018 Apr 10;137(15):1614-1631. doi: 10.1161/CIRCULATIONAHA.117.032474. Circulation. 2018. PMID: 29632154 Review.
Cited by
-
Gender-specific predictive ability for the risk of hypertension incidence related to baseline level or trajectories of adiposity indices: a cohort study of functional community.Int J Obes (Lond). 2022 May;46(5):1036-1043. doi: 10.1038/s41366-022-01081-8. Epub 2022 Feb 3. Int J Obes (Lond). 2022. PMID: 35115653
-
Heart Failure With Preserved Ejection Fraction and Adipose Tissue: A Story of Two Tales.Front Cardiovasc Med. 2019 Aug 2;6:110. doi: 10.3389/fcvm.2019.00110. eCollection 2019. Front Cardiovasc Med. 2019. PMID: 31428620 Free PMC article. Review.
-
Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production.J Endocrinol. 2017 Feb;232(2):R115-R129. doi: 10.1530/JOE-16-0237. Epub 2016 Dec 2. J Endocrinol. 2017. PMID: 27913572 Free PMC article. Review.
-
The role of lipid second messengers in aldosterone synthesis and secretion.J Lipid Res. 2022 Apr;63(4):100191. doi: 10.1016/j.jlr.2022.100191. Epub 2022 Mar 10. J Lipid Res. 2022. PMID: 35278411 Free PMC article. Review.
-
Mineralocorticoid and Estrogen Receptors in Endothelial Cells Coordinately Regulate Microvascular Function in Obese Female Mice.Hypertension. 2021 Jun;77(6):2117-2126. doi: 10.1161/HYPERTENSIONAHA.120.16911. Epub 2021 May 3. Hypertension. 2021. PMID: 33934622 Free PMC article.
References
-
- Briet M & Schiffrin EL 2011. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 13 163–172. - PubMed
-
- Capponi AM 2002. Regulation of cholesterol supply for mineralocorticoid biosynthesis. Trends Endocrinol Metab 13 118–121. - PubMed
-
- Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR & Anglo-Scandinavian Cardiac Outcomes Trial I 2007. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 839–845. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical